Recent Quotes (30 days)

You have no recent quotes
chg | %

Knight Therapeutics Inc  

(Public, CVE:GUD)   Watch this stock  
Find more results for GUD
6.14
Delayed:   3:59PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 3.51 - 7.24
Open     -
Vol / Avg. 0.00/822,875.00
Mkt cap 138.83M
P/E     -
Div/yield     -
EPS 0.00
Shares     -
Beta     -
Inst. own     -
Aug 12, 2015
Q2 2015 KNIGHT THERAPEUTICS Inc Earnings Call
Aug 12, 2015
Q2 2015 KNIGHT THERAPEUTICS Inc Earnings Release
Jun 1, 2015
Knight Therapeutics Inc at Jefferies Global Healthcare Conference
  

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 2560.97% 34451.68%
Operating margin 2304.82% -1258.19%
EBITD margin - -1234.87%
Return on average assets 6.47% -
Return on average equity 6.54% -
Employees 7 -
CDP Score - -

Address

376 Victoria Avenue, suite 220
WESTMOUNT, QC H3Z 1C3
Canada
+1-514-3401112 (Phone)
+1-514-3444675 (Fax)

Website links

Description

KNIGHT THERAPEUTICS Inc is a Canada-based specialty pharmaceutical company. The Company's principal business activity is developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products in Canada and internationally. The Company has a portfolio of products in various stages of development for various geographies that include Impavido, ATryn, Photofrin, FOCUSfactor, NXN-1882 (nNOS/5HT), NXN-4622 (nNOS) and nNOS/iNOS2 Inhibitor. Impavido (miltefosine) is a product for the treatment of leishmaniasis and is approved in a number of countries. Photofrin is a product for the treatment of oesophageal cancer, endobronchial cancer, high-grade dysplasia in Barrett's oesophagus and papillary bladder cancer and is in approved stage. FOCUSfactor is a product for dietary supplement and is in approved stage.

Officers and directors

James C. Gale Independent Chairman of the Board
Age: 65
Jonathan Ross Goodman President, Chief Executive Officer, Director
Age: 46
Jeffrey Kadanoff Chief Financial Officer
Amal Khouri Vice President - Business Development
Robert N. Lande Independent Director
Age: 52
Edward James Schutter Independent Director
Age: 63
Sylvie Tendler Independent Director